New York, NY – For decades, the complex interplay between the immune system and cancer has presented both profound challenges and groundbreaking opportunities in oncology. A central enigma has been the role of regulatory T (Treg) cells, critical immune suppressors that, in most solid tumors, are linked to worse patient outcomes due to their ability to dampen the body’s natural anti-cancer defenses. Yet, in colorectal cancer (CRC), a perplexing exception has persisted: tumors rich in Treg cells have often been associated with improved survival, baffling researchers and limiting targeted therapeutic approaches.
Now, a landmark study from the Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center (MSK) has decisively resolved this long-standing paradox. Published in the prestigious scientific journal Immunity, the findings reveal that not all Treg cells are created equal, particularly within the colorectal tumor microenvironment. The research team has made the pivotal discovery that two distinct subtypes of Treg cells exist within colorectal tumors, playing diametrically opposing roles: one acts as a formidable brake on tumor growth, while the other relentlessly fuels its progression. This groundbreaking insight not only offers a clear explanation for the colorectal cancer anomaly but also opens promising new avenues for improving immunotherapy, particularly for the vast majority of colorectal cancer patients who currently lack effective immune-based treatment options. Beyond CRC, these findings may also hold significant implications for cancers arising in other barrier tissues, such as the skin and the linings of the stomach, mouth, and throat.
"Instead of the regulatory T cells promoting tumor growth, as they do in most cancers, in colorectal cancer we discovered there are actually two distinct subtypes of Treg cells that play opposing roles — one restrains tumor growth, while the other fuels it," explains Alexander Rudensky, PhD, co-senior author of the study and Chair of the Immunology Program at MSK, and a Howard Hughes Medical Institute Investigator. "It’s these beneficial Treg cells that make the difference, and this underscores the critical need for selective therapeutic approaches that can differentiate between these cell types."
A Decades-Long Quest for Understanding
The journey to this pivotal discovery is rooted in over two decades of dedicated research by Dr. Rudensky, recognized globally as a preeminent authority on regulatory T cells. His foundational work has been instrumental in shaping our understanding of how Treg cells maintain "immune tolerance," a delicate balance that allows the immune system to distinguish between harmful pathogens and benign entities, preventing autoimmune attacks on the body’s own tissues, beneficial microbes, and everyday substances like food antigens. Over the years, his laboratory has meticulously unraveled the mechanisms governing Treg cell genesis, their intricate functions, and their profound influence on various physiological processes, including the complex landscape of cancer development.
The broader field of cancer immunology has undergone a revolutionary transformation with the advent of immunotherapy, particularly checkpoint inhibitors. These treatments have demonstrated remarkable efficacy in specific cancer types, notably those characterized by high microsatellite instability (MSI-H) and mismatch repair deficiency (MMRd), such as a subset of colorectal cancers. For these patients, immunotherapy alone can often yield durable responses, sometimes even obviating the need for aggressive surgery, chemotherapy, or radiation. However, the vast majority of colorectal cancer cases – approximately 80% to 85% – fall into the category of microsatellite stable (MSS) with proficient mismatch repair (MMRp). These tumors, which are characterized by relatively stable DNA, have historically proven refractory to checkpoint inhibitor immunotherapies, leaving a significant unmet need for innovative treatment strategies. The perplexing observation that Treg cells, typically associated with poor prognosis, correlated with better outcomes in CRC only deepened the mystery surrounding this common and deadly disease. This new MSK study directly confronts this paradox, offering a mechanistic explanation that could unlock new therapeutic pathways for MSS/MMRp colorectal cancer patients.
Illuminating the Dual Nature of Treg Cells: A Detailed Investigation
The collaborative study, spearheaded by first authors Xiao Huang, PhD, a postdoctoral researcher in the Rudensky Lab; Dan Feng, MD, PhD, a former MSK Medical Oncology fellow now at the Icahn School of Medicine at Mount Sinai; and Sneha Mitra, PhD, a postdoctoral researcher in the lab of computational biologist Christina Leslie, PhD, the study’s other senior author, embarked on a comprehensive investigation to dissect the immune landscape of colorectal cancer.
Their primary focus was on the most common form of the disease – MSS/MMRp CRC – which, despite its prevalence, remains stubbornly resistant to many modern immunotherapies. To meticulously explore the distinctive characteristics of these common colorectal cancers, the research team leveraged a sophisticated mouse model developed at MSK. This model was engineered to closely replicate the genetic alterations, behavioral patterns, and intricate immune microenvironment observed in human colorectal tumors, providing an invaluable platform for mechanistic dissection.
Through a series of rigorous experiments, the researchers made a critical distinction among tumor-associated Treg cells: they found that these cells could be broadly categorized into two principal groups based on their cytokine production. One group was characterized by its ability to produce interleukin-10 (IL-10), a potent signaling molecule often associated with immune suppression and regulation. The other group, notably, did not produce IL-10.
To ascertain the precise roles of these newly identified Treg subsets, the scientists meticulously performed experiments involving the selective removal of each group. The results unveiled stark and compelling differences in how these distinct Treg populations influenced tumor growth:
-
The Beneficial Role of IL-10-Positive Treg Cells: The study demonstrated that Treg cells producing IL-10 actively contribute to slowing tumor growth. Their primary mechanism involves reducing the activity of Th17 cells, another type of immune cell known to produce interleukin-17 (IL-17). IL-17, in this context, acts as a growth signal, promoting tumor proliferation and survival. By curbing Th17 activity and subsequent IL-17 production, IL-10-positive Tregs effectively exert an anti-tumor effect. Intriguingly, these protective Treg cells were observed to be more frequently located in the healthy tissue immediately adjacent to the tumor, suggesting a role in maintaining immune homeostasis at the tumor-host interface. Experimental validation further solidified this finding: when IL-10-positive Treg cells were selectively removed from the mouse models, tumors exhibited a noticeable acceleration in their growth rate.
-
The Harmful Role of IL-10-Negative Treg Cells: In stark contrast, the IL-10-negative Treg cells exerted a detrimental effect on anti-tumor immunity. These cells were found to suppress the activity of powerful immune defenders, most notably CD8+ T cells, which are widely recognized for their direct cytotoxic capabilities against cancer cells. This harmful subtype of Treg cells was predominantly localized within the tumor itself, suggesting a direct and potent immunosuppressive effect on the intra-tumoral immune response. The experimental evidence was equally clear: when these IL-10-negative Treg cells were eliminated, tumors experienced a significant reduction in size, highlighting their role in promoting tumor progression by disarming the body’s natural defenses.
The team’s findings were not confined to preclinical models. To ensure the translational relevance of their discoveries, the researchers meticulously confirmed these results using actual tumor samples obtained from human patients with colorectal cancer. In these patient samples, they successfully identified the same two distinct populations of IL-10-positive and IL-10-negative Treg cells. Further reinforcing the clinical significance, an analysis of outcomes from over 100 colorectal cancer patients revealed a direct correlation: patients whose tumors contained higher levels of the beneficial IL-10-positive Treg cells exhibited longer overall survival, while those whose tumors harbored a greater proportion of the harmful IL-10-negative Treg cells experienced poorer outcomes.
"This research profoundly demonstrates how important these positive cells are," states Dr. Huang. "And critically, it highlights the urgent need to develop highly specific therapies that can selectively eliminate the harmful Tregs while meticulously preserving the helpful ones, thereby tipping the immune balance in favor of the patient."
CCR8: A Promising Target for Selective Immunotherapy
Armed with this deeper understanding of Treg cell heterogeneity, the MSK team has identified a compelling therapeutic target. The findings indicate a promising path forward for significantly improving treatment options for the majority of colorectal cancer patients, particularly those with MSS/MMRp disease.
The researchers discovered that the harmful IL-10-negative Treg cells, which are primarily located within tumors and actively suppress the anti-cancer immune response, express exceptionally high levels of a specific protein called CCR8. This identification of CCR8 as a distinguishing marker for pathogenic Tregs is a critical breakthrough.
This finding builds upon earlier pioneering work from Dr. Rudensky’s laboratory, led by breast cancer surgeon George Plitas, MD. That prior research had already demonstrated that CCR8 is also highly expressed on tumor-infiltrating Treg cells in breast cancer and numerous other human malignancies. This earlier work had provocatively suggested that antibodies specifically engineered to target CCR8 could be utilized to selectively deplete these harmful Treg cells from the tumor microenvironment. The profound advantage of such an approach is its selectivity: it would allow the immune system to mount a more robust and effective attack against tumors while leaving the beneficial, protective Treg cells intact and functioning, thereby avoiding broad immunosuppression.
"This innovative idea of using CCR8-depleting antibodies, which was first pioneered here at MSK, is now the primary focus of global efforts to bring regulatory T cell-based immunotherapy into clinical practice," emphasizes Dr. Rudensky.
Indeed, the potential of this strategy is already being rigorously investigated. Multiple clinical trials are currently underway at MSK and other leading institutions worldwide, testing CCR8-targeting antibodies both as a standalone therapeutic agent and in combination with existing immunotherapies. The compelling new evidence from this study strongly strengthens the scientific rationale for deploying this highly selective strategy in colorectal cancer and, potentially, across a broader spectrum of other solid tumors.
Broader Implications: Beyond Colorectal Cancer
The research team extended their investigation beyond colorectal cancer, examining a vast dataset of T cells derived from 16 different cancer types. Their goal was to ascertain whether similar patterns of Treg cell division into IL-10-positive and IL-10-negative subsets were discernible in other malignancies. Remarkably, they uncovered analogous divisions in several cancers affecting various barrier tissues, including the skin and the delicate linings of the mouth, throat, and stomach.
"What these tissues share in common is a critical reliance on immune cells to constantly defend and repair them as they are perpetually exposed to a myriad of microbes and environmental stresses," explains Dr. Mitra, who played a leading role in the complex data analysis and is co-mentored by Dr. Leslie and Dr. Rudensky. This shared immunological context suggests that the therapeutic strategies designed to selectively remove IL-10-negative Treg cells in colorectal cancer might be equally effective against these other cancers that originate in barrier tissues, significantly broadening the potential impact of this discovery.
A Different Immune Balance in Metastatic Disease
While the findings offer immense hope for primary colorectal tumors, the researchers also uncovered a critical nuance when studying colorectal cancer that had metastasized, specifically to the liver. In these metastatic lesions, the immune landscape presented a distinct pattern: the harmful IL-10-negative Treg cells were found to vastly outnumber their beneficial IL-10-positive counterparts. This imbalance suggests a profound shift in the tumor microenvironment once the cancer spreads.
Crucially, unlike in primary tumors, the complete removal of all Treg cells in this metastatic context led to a measurable shrinkage of the metastatic tumors. This finding underscores a vital lesson: treatment strategies must be highly adaptable and account for both the specific tissue involved and the stage of disease. What works effectively for a primary tumor may require significant modification or a completely different approach for advanced, metastatic disease. This highlights the importance of continued research into the dynamic evolution of the tumor immune microenvironment at different stages of cancer progression.
Collaborative Excellence and Future Horizons
This monumental research was made possible through the dedicated efforts of a large collaborative team, including additional authors Emma Andretta, Nima Hooshdaran, Aazam Ghelani, Eric Wang, Joe Frost, Victoria Lawless, Aparna Vancheswaran, Qingwen Jiang, Cheryl Mai, and Karuna Ganesh. The Integrated Genomics Operation and the Single Cell Research Initiative at MSK played indispensable roles, providing cutting-edge technological support critical for the study’s success.
Generous funding for this transformative work was provided by prestigious organizations including the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, the Ludwig Center for Cancer Immunotherapy at MSK, the Howard Hughes Medical Institute, the Cancer Research Institute, and a Marie-Josée Kravis Fellowship in Quantitative Biology.
The implications of this study are far-reaching. By demystifying the paradoxical role of Treg cells in colorectal cancer, MSK researchers have not only resolved a long-standing scientific enigma but have also laid robust groundwork for developing more precise and effective immunotherapies. For the millions of patients battling colorectal cancer, particularly those with currently untreatable MSS/MMRp disease, this discovery offers a beacon of hope, promising a future where therapeutic interventions can be tailored to selectively target the detrimental forces within the tumor microenvironment while preserving the body’s natural defenses. The ongoing clinical trials targeting CCR8 represent the next critical step in translating this profound scientific insight into tangible benefits for patients, marking a new era in the fight against colorectal cancer and potentially a range of other challenging malignancies.
About the Author
